ENTRADA THERAPEUTICS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
ENTRADA THERAPEUTICS, INC. (TRDA) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$82.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$42.76M.
- ENTRADA THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$39.72M.
- ENTRADA THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$39.16M, a 3562.78% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$44.13M.
- ENTRADA THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$143.75M, a 319.04% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was $65.63M.
- ENTRADA THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$6.68M.
- ENTRADA THERAPEUTICS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$94.62M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$42.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$82.48M 10-Q · filed 2026-08-05 | -$121.64M derived: sum of 3 quarters · filed 2026-08-05 | -$165.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$39.72M 10-Q · filed 2026-05-07 | -$78.88M derived: sum of 2 quarters · filed 2026-05-07 | -$123.02M derived: sum of 3 quarters · filed 2026-05-07 | -$166.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$39.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$83.30M derived: sum of 2 quarters · filed 2026-02-26 | -$126.40M derived: sum of 3 quarters · filed 2026-08-05 | -$143.75M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$44.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$87.24M derived: sum of 2 quarters · filed 2026-08-05 | -$104.59M 10-Q · filed 2025-11-06 | -$103.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$43.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$60.45M 10-Q · filed 2026-08-05 | -$59.32M derived: sum of 3 quarters · filed 2026-08-05 | -$73.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$17.35M 10-Q · filed 2026-05-07 | -$16.22M derived: sum of 2 quarters · filed 2026-05-07 | -$30.25M derived: sum of 3 quarters · filed 2026-05-07 | $24.78M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$12.90M derived: sum of 2 quarters · filed 2026-02-26 | $42.13M derived: sum of 3 quarters · filed 2026-02-26 | $65.63M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$14.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $41.00M derived: sum of 2 quarters · filed 2025-11-06 | $64.50M 10-Q · filed 2025-11-06 | $54.95M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $55.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $78.53M 10-Q · filed 2025-08-06 | $68.98M derived: sum of 3 quarters · filed 2025-08-06 | $104.44M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $23.50M 10-Q · filed 2025-05-08 | $13.95M derived: sum of 2 quarters · filed 2025-05-08 | $49.41M derived: sum of 3 quarters · filed 2025-05-08 | $23.48M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$9.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $25.92M derived: sum of 2 quarters · filed 2025-02-27 | -$11.00K derived: sum of 3 quarters · filed 2025-02-27 | -$6.68M 10-K · filed 2025-02-27 |
| 2023-09-30 | $35.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $9.53M derived: sum of 2 quarters · filed 2024-11-05 | $2.86M 10-Q · filed 2024-11-05 | -$21.77M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$25.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$32.60M 10-Q · filed 2024-08-13 | -$57.23M derived: sum of 3 quarters · filed 2024-08-13 | -$82.37M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$6.67M 10-Q · filed 2024-05-07 | -$31.30M derived: sum of 2 quarters · filed 2024-05-07 | -$56.44M derived: sum of 3 quarters · filed 2024-05-07 | -$79.62M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$24.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$49.77M derived: sum of 2 quarters · filed 2024-03-13 | -$72.94M derived: sum of 3 quarters · filed 2024-03-13 | -$94.62M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$25.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$48.32M derived: sum of 2 quarters · filed 2023-11-07 | -$69.99M 10-Q · filed 2023-11-07 | -$88.43M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$23.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$44.85M 10-Q · filed 2023-08-08 | -$63.30M derived: sum of 3 quarters · filed 2023-08-08 | -$77.73M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$21.67M 10-Q · filed 2023-05-10 | -$40.12M derived: sum of 2 quarters · filed 2023-05-10 | -$54.55M derived: sum of 3 quarters · filed 2023-05-10 | -$64.45M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$18.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$32.88M derived: sum of 2 quarters · filed 2023-03-06 | -$42.78M derived: sum of 3 quarters · filed 2023-03-06 | -$51.16M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$14.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$24.33M derived: sum of 2 quarters · filed 2022-11-07 | -$32.71M 10-Q · filed 2022-11-07 | -$41.38M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$9.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$18.28M 10-Q · filed 2022-08-11 | -$26.95M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$8.38M 10-Q · filed 2022-05-12 | -$17.05M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$8.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$26.52M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | -$17.85M 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |